Chronic kidney disease–associated pruritus and quality of life with difelikefalin treatment: a post hoc analysis of phase 3 data using the Skindex-10 questionnaire
Clinical Kidney Journal · 01.10.2024 · 17 (10)
DOI: 10.1093/ckj/sfae274 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical Kidney Journal, online erschienen am 06.09.2024. Verfasst von Sonja Ständer und 7 weiteren Autor:innen. Beteiligte Einrichtung: Center for Chronic Pruritus, University of Münster, Münster, Germany. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Vifor Fresenius Medical Care Renal Pharma Ltd.
Abstract (Originalsprache)
Background
Pruritus is a common condition in chronic kidney disease (CKD), especially for patients receiving haemodialysis. CKD-associated pruritus (CKD-aP) can be distressing and have a negative impact on quality of life (QoL). This post hoc analysis aimed to assess the relationship between pruritus relief and QoL.
Methods
Data from phase 3 trials [(NCT03422653, NCT03636269 grouped), and NCT03998163] of the novel antipruritic difelikefalin (N = 914) were used to assess the relationship between reductions in pruritus intensity at Week 12 (24-h Worst Itching Intensity Numeric Rating Scale; WI-NRS), perceived improvement in itch (Patient Global Impression of Change, PGI-C) and pruritus-related QoL (Skindex-10 questionnaire).
Results
Patients receiving difelikefalin had greater improvements in Skindex-10 total scores than those receiving placebo [LS mean treatment difference –3.4; 95% confidence interval (CI) –5.5, –1.3; P = .002] and greater improvements across Skindex-10 domains (disease, mood and social functioning) at Week 12. In patients receiving difelikefalin, those with clinically meaningful improvements in pruritus (≥3-point reduction in WI-NRS score) at Week 12 had a greater improvement in Skindex-10 total score (mean difference 14.2; 95% CI 11.0, 17.3; P < .001) and Skindex-10 domains than those with a <3-point reduction in WI-NRS score. Improvements in Skindex-10 total scores correlated with PGI-C.
Conclusions
Improvements in pruritus intensity following 12 weeks of treatment with difelikefalin were associated with improvements in QoL. Larger improvements in Skindex-10 scores were seen in patients with a greater reduction in pruritus intensity, indicating that improvements in pruritus are associated with a range of factors, such as mood and social functioning, that affect pruritus-related QoL.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Center for Chronic Pruritus, University of Münster, Münster, Germany.
- Northwell Health, Great Neck, New York, NY, USA.
- CSL Vifor, Glattbrugg, Zurich, Switzerland.
- Cara Therapeutics Inc., Stamford, CT, USA.
- University of California Irvine, Irvine, CA, USA.
ORCID-Profile: Kamyar Kalantar-Zadeh
Förderung
- Vifor Fresenius Medical Care Renal Pharma Ltd
Zitieren
APA
Ständer, S., Fishbane, S., Schaufler, T., Ruessmann, D., Morin, I., Menzaghi, F., Wen, W., & Kalantar-Zadeh, K. (2024). Chronic kidney disease–associated pruritus and quality of life with difelikefalin treatment: a post hoc analysis of phase 3 data using the Skindex-10 questionnaire. Clinical Kidney Journal, 17(10). https://doi.org/10.1093/ckj/sfae274
Vancouver
Ständer S, Fishbane S, Schaufler T, Ruessmann D, Morin I, Menzaghi F, et al. Chronic kidney disease–associated pruritus and quality of life with difelikefalin treatment: a post hoc analysis of phase 3 data using the Skindex-10 questionnaire. Clinical Kidney Journal. 2024;17(10). doi:10.1093/ckj/sfae274
BibTeX
@article{Stnder2024,
author = {Ständer, Sonja and Fishbane, Steven and Schaufler, Thilo and Ruessmann, Despina and Morin, Isabelle and Menzaghi, Frédérique and Wen, Warren and Kalantar-Zadeh, Kamyar},
title = {Chronic kidney disease–associated pruritus and quality of life with difelikefalin treatment: a post hoc analysis of phase 3 data using the Skindex-10 questionnaire},
journal = {Clinical Kidney Journal},
year = {2024},
volume = {17},
number = {10},
doi = {10.1093/ckj/sfae274}
}
EUVIMED